Cancer Research Annual Meeting 2010 Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guo, F.
Right arrow Articles by Bhalla, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guo, F.
Right arrow Articles by Bhalla, K.
[Cancer Research 64, 2580-2589, April 1, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells

Fei Guo1, Celia Sigua1, Jianguo Tao1, Purva Bali1, Prince George1, Yunqing Li1, Sylvie Wittmann1, Lynn Moscinski1, Peter Atadja2 and Kapil Bhalla1

1 Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute University of South Florida, Tampa, Florida, and 2 Novartis Pharmaceutical Inc., Summit, New Jersey

Present studies demonstrate that treatment with the histone deacetylases inhibitor LAQ824, a cinnamic acid hydroxamate, increased the acetylation of histones H3 and H4, as well as induced p21WAF1 in the human T-cell acute leukemia Jurkat, B lymphoblast SKW 6.4, and acute myelogenous leukemia HL-60 cells. This was associated with increased accumulation of the cells in the G1 phase of the cell cycle, as well as accompanied by the processing and activity of caspase-9 and -3, and apoptosis. Exposure to LAQ824 increased the mRNA and protein expressions of the death receptors DR5 and/or DR4, but reduced the mRNA and protein levels of cellular FLICE-inhibitory protein (c-FLIP). As compared with treatment with Apo-2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or LAQ824 alone, pretreatment with LAQ824 increased the assembly of Fas-associated death domain and caspase-8, but not of c-FLIP, into the Apo-2L/TRAIL-induced death-inducing signaling complex. This increased the processing of caspase-8 and Bcl-2 interacting domain (BID), augmented cytosolic accumulation of the prodeath molecules cytochrome-c, Smac and Omi, as well as led to increased activity of caspase-3 and apoptosis. Treatment with LAQ824 also down-regulated the levels of Bcl-2, Bcl-xL, XIAP, and survivin. Partial inhibition of apoptosis due to LAQ824 or Apo-2L/TRAIL exerted by Bcl-2 overexpression was reversed by cotreatment with LAQ824 and Apo-2L/TRAIL. Significantly, cotreatment with LAQ824 increased Apo-2L/TRAIL-induced apoptosis of primary acute myelogenous leukemia blast samples isolated from 10 patients with acute myelogenous leukemia. Taken together, these findings indicate that LAQ824 may have promising activity in augmenting Apo-2L/TRAIL-induced death-inducing signaling complex and apoptosis of human acute leukemia cells.




This article has been cited by other articles:


Home page
 haematolHome page
E. W. Schaefer, A. Loaiza-Bonilla, M. Juckett, J. F. DiPersio, V. Roy, J. Slack, W. Wu, K. Laumann, I. Espinoza-Delgado, S. D. Gore, et al.
A phase 2 study of vorinostat in acute myeloid leukemia
Haematologica, October 1, 2009; 94(10): 1375 - 1382.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. C. Crisanti, A. F. Wallace, V. Kapoor, F. Vandermeers, M. L. Dowling, L. P. Pereira, K. Coleman, B. G. Campling, Z. G. Fridlender, G. D. Kao, et al.
The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
Mol. Cancer Ther., August 1, 2009; 8(8): 2221 - 2231.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Ellis, M. Bots, R. K. Lindemann, J. E. Bolden, A. Newbold, L. A. Cluse, C. L. Scott, A. Strasser, P. Atadja, S. W. Lowe, et al.
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy
Blood, July 9, 2009; 114(2): 380 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Piekarz and S. E. Bates
Epigenetic Modifiers: Basic Understanding and Clinical Development
Clin. Cancer Res., June 15, 2009; 15(12): 3918 - 3926.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Chen, W. Fiskus, K. Eaton, P. Fernandez, Y. Wang, R. Rao, P. Lee, R. Joshi, Y. Yang, R. Kolhe, et al.
Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism
Blood, April 23, 2009; 113(17): 4038 - 4048.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
K. N. Bhalla
Combined Therapy with Agents Targeted against Deregulated Epigenetic Mechanisms in Cancer
Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 233 - 236.
[Full Text] [PDF]

Home page
 BloodHome page
G. Gobbi, P. Mirandola, C. Carubbi, C. Micheloni, C. Malinverno, P. Lunghi, A. Bonati, and M. Vitale
Phorbol ester-induced PKC{epsilon} down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation
Blood, March 26, 2009; 113(13): 3080 - 3087.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. L. Tazzari, G. Tabellini, F. Ricci, V. Papa, R. Bortul, F. Chiarini, C. Evangelisti, G. Martinelli, A. Bontadini, L. Cocco, et al.
Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells
Cancer Res., November 15, 2008; 68(22): 9394 - 9403.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Bazzaro, Z. Lin, A. Santillan, M. K. Lee, M.-C. Wang, K. C. Chan, R. E. Bristow, R. Mazitschek, J. Bradner, and R. B.S. Roden
Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor
Clin. Cancer Res., November 15, 2008; 14(22): 7340 - 7347.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Fiskus, Y. Wang, R. Joshi, R. Rao, Y. Yang, J. Chen, R. Kolhe, R. Balusu, K. Eaton, P. Lee, et al.
Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells
Clin. Cancer Res., October 1, 2008; 14(19): 6106 - 6115.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Fiskus, R. Rao, P. Fernandez, B. Herger, Y. Yang, J. Chen, R. Kolhe, A. Mandawat, Y. Wang, R. Joshi, et al.
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells
Blood, October 1, 2008; 112(7): 2896 - 2905.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. J. Frew, R. K. Lindemann, B. P. Martin, C. J. P. Clarke, J. Sharkey, D. A. Anthony, K.-M. Banks, N. M. Haynes, P. Gangatirkar, K. Stanley, et al.
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
PNAS, August 12, 2008; 105(32): 11317 - 11322.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Dalgard, K. R. Van Quill, and J. M. O'Brien
Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma
Clin. Cancer Res., May 15, 2008; 14(10): 3113 - 3123.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Nakahara, M. Takeuchi, I. Kinoyama, T. Minematsu, K. Shirasuna, A. Matsuhisa, A. Kita, F. Tominaga, K. Yamanaka, M. Kudoh, et al.
YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts
Cancer Res., September 1, 2007; 67(17): 8014 - 8021.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. T. Nawrocki, J. S. Carew, L. Douglas, J. L. Cleveland, R. Humphreys, and J. A. Houghton
Histone Deacetylase Inhibitors Enhance Lexatumumab-Induced Apoptosis via a p21Cip1-Dependent Decrease in Survivin Levels
Cancer Res., July 15, 2007; 67(14): 6987 - 6994.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Li, X. Zhang, and A. F. Olumi
MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L)
Cancer Res., March 1, 2007; 67(5): 2247 - 2255.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. B. Arnold, N. Arkus, J. Gunn, and M. Korc
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Growth Inhibition and Enhances Gemcitabine-Induced Cell Death in Pancreatic Cancer
Clin. Cancer Res., January 1, 2007; 13(1): 18 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
V. Baradari, A. Huether, M. Hopfner, D. Schuppan, and H. Scherubl
Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1237 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. S. Tsai, W.-S. Yeow, A. Chua, R. M. Reddy, D. M. Nguyen, D. S. Schrump, and D. M. Nguyen
Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin
Mol. Cancer Ther., December 1, 2006; 5(12): 2977 - 2990.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. K. Kulp, C.-S. Chen, D.-S. Wang, C.-Y. Chen, and C.-S. Chen
Antitumor Effects of a Novel Phenylbutyrate-Based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer
Clin. Cancer Res., September 1, 2006; 12(17): 5199 - 5206.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Fiskus, M. Pranpat, P. Bali, M. Balasis, S. Kumaraswamy, S. Boyapalle, K. Rocha, J. Wu, F. Giles, P. W. Manley, et al.
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Blood, July 15, 2006; 108(2): 645 - 652.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Inoue, A. Mai, M. J.S. Dyer, and G. M. Cohen
Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis.
Cancer Res., July 1, 2006; 66(13): 6785 - 6792.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Basu, V. P. Castle, M. Bouziane, K. Bhalla, and S. Haldar
Crosstalk between Extrinsic and Intrinsic Cell Death Pathways in Pancreatic Cancer: Synergistic Action of Estrogen Metabolite and Ligands of Death Receptor Family.
Cancer Res., April 15, 2006; 66(8): 4309 - 4318.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. A. Matthews, P. Liu, M. Spitaler, E. N. Olson, T. A. McKinsey, D. A. Cantrell, and A. M. Scharenberg
Essential Role for Protein Kinase D Family Kinases in the Regulation of Class II Histone Deacetylases in B Lymphocytes
Mol. Cell. Biol., February 15, 2006; 26(4): 1569 - 1577.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
R. R. Rosato, S. C. Maggio, J. A. Almenara, S. G. Payne, P. Atadja, S. Spiegel, P. Dent, and S. Grant
The Histone Deacetylase Inhibitor LAQ824 Induces Human Leukemia Cell Death through a Process Involving XIAP Down-Regulation, Oxidative Injury, and the Acid Sphingomyelinase-Dependent Generation of Ceramide
Mol. Pharmacol., January 1, 2006; 69(1): 216 - 225.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Guo, K. Rocha, P. Bali, M. Pranpat, W. Fiskus, S. Boyapalle, S. Kumaraswamy, M. Balasis, B. Greedy, E. S. M. Armitage, et al.
Abrogation of Heat Shock Protein 70 Induction as a Strategy to Increase Antileukemia Activity of Heat Shock Protein 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin
Cancer Res., November 15, 2005; 65(22): 10536 - 10544.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. R. Rosato, J. A. Almenara, S. C. Maggio, P. Atadja, R. Craig, J. Vrana, P. Dent, and S. Grant
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells
Mol. Cancer Ther., November 1, 2005; 4(11): 1772 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Bali, M. Pranpat, R. Swaby, W. Fiskus, H. Yamaguchi, M. Balasis, K. Rocha, H.-G. Wang, V. Richon, and K. Bhalla
Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2
Clin. Cancer Res., September 1, 2005; 11(17): 6382 - 6389.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. L. Bevins and S. G. Zimmer
It's About Time: Scheduling Alters Effect of Histone Deacetylase Inhibitors on Camptothecin-Treated Cells
Cancer Res., August 1, 2005; 65(15): 6957 - 6966.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, et al.
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90: A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS
J. Biol. Chem., July 22, 2005; 280(29): 26729 - 26734.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. N. Bhalla
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. C. Drummond, C. Marx, Z. Guo, G. Scott, C. Noble, D. Wang, M. Pallavicini, D. B. Kirpotin, and C. C. Benz
Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes
Clin. Cancer Res., May 1, 2005; 11(9): 3392 - 3401.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Guo, C. Sigua, P. Bali, P. George, W. Fiskus, A. Scuto, S. Annavarapu, A. Mouttaki, G. Sondarva, S. Wei, et al.
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells
Blood, February 1, 2005; 105(3): 1246 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Papageorgiou, L. Lashinger, R. Millikan, H. B. Grossman, W. Benedict, C. P. N. Dinney, and D. J. McConkey
Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Interferon-Induced Apoptosis in Human Bladder Cancer Cells
Cancer Res., December 15, 2004; 64(24): 8973 - 8979.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Bali, P. George, P. Cohen, J. Tao, F. Guo, C. Sigua, A. Vishvanath, A. Scuto, S. Annavarapu, W. Fiskus, et al.
Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3
Clin. Cancer Res., August 1, 2004; 10(15): 4991 - 4997.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.